Vlado Perkovic

Jan 23, 2025 | onlinelibrary.wiley.com | Safia Chatur |Muthiah Vaduganathan |Robert Fletcher |Vlado Perkovic

Introduction Patients with type 2 diabetes face heightened risk for the development of comorbid cardiovascular and kidney disease including heart failure (HF).1 The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin has been shown to reduce the risk of HF hospitalization or cardiovascular death among patients with type 2 diabetes at high cardiovascular and kidney risk across a broad range of patient subgroups in the CANVAS and CREDENCE trials, respectively.2, 3 Loop diuretics are...

Jul 12, 2024 | radcliffecardiology.com | Vlado Perkovic |Kevin Cheng |Jonathan Hill |Pam R Taub

ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153). The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median follow-up period was 3.4 years, as the trial was stopped early at a prespecified interim analysis.

Mar 9, 2023 | medicalxpress.com | Vlado Perkovic

For the first time, we have the tools to greatly reduce kidney disease. How can we make sure they get to those who need them? For the first time in 20 years, two new classes of drugs have become available in Australia for the treatment of diabetic kidney disease, the most common cause of kidney failure. Both are extremely effective, safe, and relatively affordable. However, too few people with kidney disease are using these breakthrough drugs.